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Obesity has been posited as an independent risk factor
for diabetic kidney disease (DKD), but establishing cau-
sality from observational data is problematic. We aimed
to test whether obesity is causally related to DKD using
Mendelian randomization, which exploits the random as-
sortment of genes during meiosis. In 6,049 subjects with
type 1 diabetes, we used a weighted genetic risk score
(GRS) comprised of 32 validated BMI loci as an instrument
to test the relationship of BMI with macroalbuminuria,
end-stage renal disease (ESRD), or DKD defined as pres-
ence of macroalbuminuria or ESRD. We compared these
results with cross-sectional and longitudinal obser-
vational associations. Longitudinal analysis demon-
strated a U-shaped relationship of BMI with development
of macroalbuminuria, ESRD, or DKD over time. Cross-
sectional observational analysis showed no association
with overall DKD, higher odds of macroalbuminuria (for
every 1 kg/m2 higher BMI, odds ratio [OR] 1.05, 95% CI
1.03–1.07, P < 0.001), and lower odds of ESRD (OR 0.95,
95% CI 0.93–0.97, P < 0.001). Mendelian randomization
analysis showed a 1 kg/m2 higher BMI conferring an in-
creased risk in macroalbuminuria (OR 1.28, 95% CI
1.11–1.45, P = 0.001), ESRD (OR 1.43, 95% CI 1.20–
1.72, P < 0.001), and DKD (OR 1.33, 95% CI 1.17–1.51,
P < 0.001). Our results provide genetic evidence for a
causal link between obesity and DKD in type 1 diabe-
tes. As obesity prevalence rises, this finding predicts
an increase in DKD prevalence unless intervention
should occur.
Diabetic kidney disease (DKD) is a devastating complica-
tion of diabetes and is the major cause of end-stage renal
disease (ESRD) in the U.S., where the incidence of ESRD
has nearly doubled over the past two decades (1). Al-
though tight glycemic control in type 1 diabetes can re-
duce the rates of DKD and ESRD (2,3), a substantial
number of patients develop DKD despite adequate glyce-
mic control, while others with chronic severe hyperglyce-
mia are relatively spared (4). Obesity has been posited as
an independent risk factor for both diabetic (5,6) and
nondiabetic (7–11) renal disease. However, epidemiologic
studies have produced conflicting results, and establishing
causality from observational data is difficult (6,12).
Mendelian randomization has emerged as a novel and
powerful approach to assess causality, free from the limi-
tations of traditional observational studies and the oper-
ational constraints of randomized controlled trials. Given
the principle of random assortment of gene variants
during meiosis, Mendelian randomization is considered
analogous to a randomized controlled trial, where expo-
sure groups are defined by genotype. Others have exploited
the heritable nature of obesity in Mendelian randomization
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studies to assess the causality of obesity on a variety of car-
diometabolic phenotypes, using genetic variants, either in-
dividually or in combination, associated with BMI (13–15).
In this study, we use Mendelian randomization to evaluate
the causal relationship between obesity and DKD (Fig. 1),
comparing and contrasting with cross-sectional and lon-
gitudinal observational associations.
RESEARCH DESIGN AND METHODS
Study Design
The study design consisted of two components. First, in a
cohort of Finnish participants with type 1 diabetes assessed
longitudinally for renal complications, we evaluated the
association of obesity at the initial visit with the likeli-
hood of developing DKD over time. Second, using a case-
control design, we compared the observational association
of BMI and DKD with Mendelian randomization analysis
of BMI and DKD, using a weighted genetic risk score of
BMI-raising alleles as an instrument.
Study Participants
Three case-control cohorts previously participating in the
Genetics of Nephropathy—An International Effort (GENIE)
consortium (16) contributed genetic and phenotypic
data to this study: the Genetics of Kidneys in Diabetes
US Study (US-GoKinD [17]); the All Ireland-Warren
3-Genetics of Kidneys in Diabetes U.K. and Republic of
Ireland (UK-ROI [18]) Collection; and the Finnish Diabetic
Nephropathy Study (FinnDiane [19]). The GoKinD and UK-
ROI studies were both cross-sectional in nature, with risk
factors and renal status assessed at one time point. The
FinnDiane study is an ongoing longitudinal study with
baseline examinations beginning in 1998 and follow-up
examinations since 2004. Subject recruitment has previ-
ously been described elsewhere (20). In brief, study par-
ticipants attended a regular visit to their physician, during
which they were assessed for both micro- and macrovas-
cular complications. For this particular study, FinnDiane
patients with BMI and genotype data available were in-
cluded. Data were extracted from medical files and hospi-
tal discharge registries to complement the information
from follow-up examination. The study protocol is in ac-
cordance with the Declaration of Helsinki and was approved
by the local ethics committee at each study center. Each
study participant gave written informed consent prior to
participation.
For the cross-sectional analyses, all cases had a di-
agnosis of type 1 diabetes for at least 10 years and were
classified as having macroalbuminuria and ESRD. Normal
control subjects were defined as individuals with type 1
diabetes for at least 15 years and no evidence of renal
disease (Supplementary Table 1). For the longitudinal
analyses in the FinnDiane cohort, we included subjects
with type 1 diabetes of any duration and no ESRD at
baseline with available follow-up data (Supplementary
Fig. 1).
Phenotype Definitions
The phenotype of DKD is now considered to be more
complex than the traditional paradigm of steady, in-
exorable progression from microalbuminuria to macro-
albuminuria and ultimately ESRD (16,21–23). Therefore,
we studied three definitions of DKD: a broad definition
including subjects with either ESRD or macroalbuminuria
as case subjects, a stringent definition of case subjects as
those with ESRD alone, and case subjects with macroal-
buminuria alone. BMI was calculated as weight in kilo-
grams divided by the square of height in meters.
In the longitudinal analyses, we studied 1) progres-
sion from normal albumin excretion rate (AER) or micro-
albuminuria to broadly defined DKD (macroalbuminuria
or ESRD), 2) progression from normal AER or micro-
albuminuria to macroalbuminuria, and 3) progression
from normal AER, microalbuminuria, or macroalbuminuria
to ESRD. In addition, we studied “any progression,”
with any new renal event defined as the development
of microalbuminuria, macroalbuminuria, or ESRD during
follow-up.
Genetic Instruments
Statistical power for Mendelian randomization can be
improved by use of multiple genetic variants combined to
Figure 1—Schematic overview of Mendelian randomization. A:
Since the observed association between a given risk factor and
outcome may be influenced by confounders, a genetic variant
that has a direct association with the intermediate risk factor can
be used to assess the causal relationship between risk factor and
outcome. Note three key assumptions inherent in this depiction: 1)
the variant is independent of the confounders, 2) the variant is re-
liably associated with the intermediate risk factor, and 3) there is no
direct effect of the variant on the outcome (i.e., bypassing the risk
factor). B: In our study, we used a genetic risk score as an instru-
ment for BMI to evaluate the causal relationship of BMI and DKD.
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give a higher predictive value (24). Therefore, we chose to
use a weighted genetic risk score as an instrument for
BMI. We calculated our weighted genetic risk score using
the 32 lead single nucleotide polymorphisms (SNPs)
reported in the largest European genome-wide association
study of obesity published by Speliotes et al. (25) at the
time of study design. The score was calculated by summing
up the number of risk alleles at each locus, multiplied by
the effect size at each locus as reported by Speliotes et al.,
using the PLINK “–score” routine (26). Genotyping and
imputation were performed as previously reported (16).
GenGen (http://www.openbioinformatics.org) was used to
convert the imputed dosage data to most likely genotypes
using a threshold of 90% for the genotypic posterior prob-
ability. When direct or imputed genotype data were not
available at a given locus, the expected value was imputed
based on the cohort allele frequency. In the UK-ROI cohort,
all subjects had genotype data for at least 30 of the 32 loci.
In the FinnDiane cohort, all subjects had genotype data
for 28 of 31 loci. (One locus had a high rate of missingness
and was excluded for all subjects.) In the US-GoKinD co-
hort, 1,408 (80%) of subjects had information for at least
29 of 32 loci; analyses were run with and without sub-
jects having information at ,29 loci and were not signif-
icantly different.
Statistical Analysis
Analyses were performed using either Stata, version 12.1
(StataCorp, College Station, TX), or R (http://www.r-
project.org).
Longitudinal Analysis
Using longitudinal data from the FinnDiane study, we
assessed the effect of obesity on incident DKD by Cox
proportional hazards model with BMI predicting time to
DKD progression, adjusted for baseline age, sex, and
diabetes duration. BMI was studied both as a continuous
and categorical variable, divided into quintiles, with the
second quintile used as a reference. In addition, the
linearity assumption was tested by fitting a model where
BMI was included as a restricted cubic spline with three
knots located at the 10th, 50th, and 90th percentiles of
BMI (corresponding to 20.99 kg/m2, 24.84 kg/m2, and
29.97 kg/m2). The number and location of knots used
to fix splines in the modeling followed previous recom-
mendations (27). The reference value for hazard ratios in
the restricted cubic spline model was set to median BMI
(24.84 kg/m2), and Wald tests for linearity were used for
testing nonlinear effects.
Association Analysis
Using cross-sectional data from all cohorts, we examined
the association of BMI with the genetic risk score using
linear regression. The observational estimates of odds
ratios (ORs) of each outcome per 1 kg/m2 higher BMI,
adjusted for age, sex, and diabetes duration, were assessed
using logistic regression.
Mendelian Randomization
Instrumental variable analysis was used to estimate the
causal effect per 1 kg/m2 higher BMI on DKD outcome,
using the logistic control function estimator method
(28). In this two-stage method, we first performed a lin-
ear regression of BMI on the weighted genetic risk score.
The predicted BMI from stage 1 was then used as the
independent predictor for DKD outcome in the stage
2 logistic regression, adjusting for the residuals from
stage 1. The second stage regression was adjusted for
age, sex, and diabetes duration. To assess whether our
results were influenced by pleiotropy, we performed
a sensitivity analysis using two subsets of the original
genetic risk score: one excluding SNPs with nominally
significant effects on other metabolic traits (HDL and
LDL cholesterol, triglycerides, fasting glucose, fasting
insulin, HOMA of insulin resistance, HOMA of b-cell
function, 2-h glucose, and type 2 diabetes risk) and
one including only SNPs found within genes associated
with monogenic obesity syndromes (MC4R, POMC,
BDNF, and SH2B1). Finally, we performed a statistical
comparison of observational and Mendelian random-
ization analyses using the method of Altman and
Bland (29).
RESULTS
Baseline characteristics of FinnDiane longitudinal partic-
ipants are shown in Table 1 and of the three cohorts
participating in the cross-sectional analysis in Table 2.
Table 1—Baseline characteristics of participants in the longitudinal FinnDiane cohort by DKD status
Normal AER Microalbuminuria Macroalbuminuria ESRD
N 1,538 447 593 319
BMI (kg/m2) 25.1 6 3.3 25.7 6 3.6 26.0 6 4.0 24.1 6 3.8
Women (%) 56.9 40.8 40.3 40.4
Age (years) 40.4 6 12.0 39.3 6 12.0 41.7 6 10.4 45.6 6 8.5
Duration of diabetes (years) 24.4 6 9.9 25.9 6 10.5 28.5 6 8.0 33.0 6 8.14
HbA1c (%) 8.2 6 1.3 8.8 6 1.5 9.1 6 1.6 8.6 6 1.5
HbA1c (mmol/mol) 66 6 14.2 73 6 16.4 76 6 17.5 70 6 16.4
Data are means 6 SD unless otherwise indicated. N, number of participants.
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For the longitudinal analysis, 2,392 participants (1,386
normoalbuminuric, 401 microalbuminuric, and 605 mac-
roalbuminuric) were followed for a median duration of
6.5 years. In the cross-sectional analysis, there were
1,040 participants with ESRD, 1,307 participants with
macroalbuminuria, and 2,900 control subjects without
any clinical evidence of kidney disease.
We first examined the longitudinal FinnDiane cohort to
test the observational relationship of BMI with time to
DKD, using the selected end points as outlined above. At
the follow-up visit, renal disease progression had occurred
for 17.6% (N = 420). There was no significant linear re-
lationship of BMI with any of the DKD outcomes in the Cox
proportional hazards model. Analysis by BMI quintiles dem-
onstrated a U-shaped relationship between obesity and pro-
gression of DKD, with higher risk in the lowest and highest
quintiles, for all outcomes (Table 3; Fig. 2). In addition, we
obtained significant P values for nonlinear effects in the re-
stricted cubic spline model supporting the existence of
a nonlinear, U-shaped relationship for BMI and progression
to DKD (P = 0.018) as well as progression to macroalbumin-
uria (P = 0.019) and ESRD (P , 0.001) (Fig. 2).
Using our cross-sectional data from all three cohorts,
we examined the association of BMI with presence of any
of the three DKD definitions outlined above (Fig. 3, left
panel). There was no significant association of BMI with
broadly defined DKD in any of the three cohorts (com-
bined OR for per 1 kg/m2 higher BMI 1.00, 95% CI 0.99–
1.02, P = 0.62). Higher BMI was associated with increased
odds of macroalbuminuria alone (OR 1.05, 95% CI 1.03–
1.07, P, 0.001). For ESRD alone, the odds were lower for
each 1 kg/m2 higher BMI (OR 0.95, 95% CI 0.93–0.97,
P , 0.001).
We proceeded to perform a Mendelian randomiza-
tion analysis, using genetic variants associated with
elevated BMI, to assess the causal effect of higher BMI
over the life span on development of DKD. First, to
validate the association of the selected BMI-raising
alleles in our cohorts, we performed a linear regression
of BMI on the weighted genetic risk score. Meta-
analysis of the three studies showed that BMI was
higher by 0.42 kg/m2 per 1 SD of the weighted genetic
risk score (95% CI 0.32–0.52, P , 0.001). The results
were similar across all participants, regardless of pro-
teinuria or ESRD status.
Next, we used the weighted genetic risk score in an
instrumental analysis of BMI with each of our defined
DKD outcomes. We observed evidence for causality of
BMI as determined by genetics with all three DKD
outcomes (Fig. 3, right panel). For every 1 kg/m2 higher
BMI, meta-analysis showed an overall increased odds of
broadly defined DKD (combined OR 1.33, 95% CI 1.17–
1.51, P , 0.001), macroalbuminuria alone (OR 1.28, 95%
CI 1.11–1.45, P = 0.001), and ESRD alone (OR 1.43, 95%
CI 1.20–1.72, P , 0.001) in the combined total of all
three cohorts. Results did not change significantly after
adjustment for population stratification with principal
components. Sensitivity analyses using subsets of the
original genetic risk score to minimize pleiotropy showed
a direction of effect consistent with our original findings
for both subsets (data not shown).
In summary, cross-sectional observational analysis of
the association of BMI with DKD showed no increased risk
of ESRD or the combined phenotype of macroalbuminuria
plus ESRD but a 5% increased risk of macroalbuminuria
for every 1 kg/m2 higher BMI. In a longitudinal observa-
tional analysis, there appeared to be a U-shaped relation-
ship of BMI with development of DKD over time, with
increased risk for the lowest and highest quintiles of BMI.
With Mendelian randomization analysis, there appeared
to be a causal association with BMI as determined by genetics
and any of the three DKD outcomes, with a 1 kg/m2 higher
BMI conferring a 28% increased risk in macroalbuminuria
alone, a 43% increased risk in ESRD alone, and a 33% in-
creased risk of DKD defined as either macroalbuminuria or
ESRD.
DISCUSSION
In this study, we used Mendelian randomization to
assess causality of obesity on DKD and compared our
Table 2—Baseline characteristics of participants in the cross-sectional US-GoKinD, UK-ROI, and FinnDiane cohorts by DKD
status
US-GoKinD UK-ROI FinnDiane
No DKD DKD No DKD DKD No DKD DKD
N 807 761 831 674 1,262 912
BMI (kg/m2) 26.1 6 8.6 25.7 6 5.2 26.2 6 4.1 26.3 6 4.7 25.1 6 3.33 25.3 6 4.0
Women (%) 58.4 48.2 55.7 40.4 57.5 40.8
Age (years) 38.5 6 8.6 43.2 6 6.9 41.6 6 11.0 48.4 6 10.6 42.4 6 11.6 43.1 6 10.0
Duration of diabetes (years) 25.5 6 7.7 31.3 6 7.8 27.1 6 8.6 33.5 6 9.5 27.1 6 9.0 30.0 6 8.3
HbA1c (%) 7.5 6 1.2 7.5 6 1.9 8.6 6 1.6 8.9 6 1.8 8.2 6 1.3 8.9 6 1.6
HbA1c (mmol/mol) 58 6 13.1 58 6 20.8 70 6 17.5 74 6 19.7 66 6 14.2 74 6 17.5
ESRD (%) 0 65.4 0 33.1 0 35.0
Values are means 6 SD except where indicated. N, number of participants.
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results with both cross-sectional and longitudinal
observational associations of BMI and DKD. The ob-
servational data hint at a relationship of obesity with
DKD, but the findings do not lead to a straightforward
interpretation. In the cross-sectional analysis, there is a
positive association of risk of macroalbuminuria with
increasing BMI, but ESRD is associated with lower
BMI; this finding may represent reverse causation, as
patients with ESRD are ill and often cachectic. The
longitudinal analysis shows that subjects at the highest
and lowest quintiles of BMI were both at higher risk of
being diagnosed with kidney disease at follow-up; it is
unclear whether leanness is itself a risk factor for
disease or a marker that the disease process is present
but has not reached a threshold for diagnosis at first
evaluation. In contrast, the Mendelian randomization
analysis supports the conclusion of a causal role for
obesity in the development of DKD, whether defined by
presence of proteinuria or more strictly by progression
to ESRD.
The validity of these findings depends on several key
assumptions required for Mendelian randomization: 1)
that the genetic instrument is independent of any con-
founders, 2) that the genetic instrument is reliably asso-
ciated with the intermediate phenotype, and 3) that the
genetic instrument is independent of the outcome; i.e.,
the genetic variant does not have a direct effect on the
outcome other than through the intermediate phenotype
(30). Both the first and third assumptions are subject to
violation from population stratification and pleiotropic
effects (either directly or from genes in linkage disequi-
librium with the variant used). In this study, inclusion of
principal components in the analysis did not change the
results significantly. The use of multiple variants in a ge-
netic risk score, as used in this study, may help balance
out the effect of pleiotropy in the sense of a given indi-
vidual variant affecting multiple phenotypes (31,32), al-
though systematic pleiotropic effects across many loci
could still theoretically be present. (Neither this nor any
other Mendelian randomization approach rules out indi-
rect causal effects in the form of downstream events; i.e.,
higher BMI causally leads to increased blood pressure,
which in turn increases DKD risk.) When we performed
sensitivity analysis using two different subsets of the BMI
genetic risk score, our results were directionally consis-
tent for both subsets, suggesting that pleiotropy does not
explain our results. With regard to the second assump-
tion, the variants used in our genetic risk score were pre-
viously validated in a large, well-constructed genome-wide
association study meta-analysis of obesity and were
strongly associated with BMI in all three of our cohorts.
We used multiple variants and a weighted score to in-
crease precision (24). These variants together only ex-
plain 1.45% of the variance in BMI (25), limiting the
power of our analysis. We sought to maximize power
by combining findings from three separate cohorts;
the overall consistency observed between these three
T
ab
le
3—
Lo
ng
itu
d
in
al
as
so
ci
at
io
n
o
f
B
M
I
w
it
h
D
K
D
o
ut
co
m
es
Q
ui
nt
ile
(B
M
I
ra
ng
e)
,
kg
/m
2
M
ac
ro
or
E
S
R
D
N
M
ac
ro
al
on
e
N
E
S
R
D
al
on
e
N
A
ny
pr
og
re
ss
io
n
N
1
(1
4.
99
–
22
.2
8)
2.
05
(1
.0
9–
3.
86
),
0.
02
6
30
9
2.
33
(1
.1
9–
4.
58
),
0.
01
4
30
9
2.
04
(1
.3
6–
3.
07
),
5.
5
3
10
2
4
39
4
1.
92
(1
.3
9–
2.
65
),
7.
2
3
10
2
5
42
7
2
(2
2.
28
–
24
.0
3)
1.
00
37
9
1.
00
37
6
1.
00
45
4
1.
00
47
3
3
(2
4.
03
–
25
.7
1)
0.
92
(0
.4
5–
1.
90
),
0.
82
34
9
0.
94
(0
.4
2–
2.
07
),
0.
87
34
7
1.
31
(0
.8
6–
1.
98
),
0.
21
46
0
1.
21
(0
.8
7–
1.
70
),
0.
26
47
9
4
(2
5.
72
–
27
.9
9)
1.
48
(0
.7
9–
2.
78
),
0.
23
34
8
1.
56
(0
.7
9–
3.
10
),
P
=
0.
20
34
5
0.
73
(0
.4
6–
1.
17
),
0.
19
44
5
1.
08
(0
.7
7–
1.
51
),
0.
67
48
5
5
(2
7.
99
–
52
.4
5)
1.
95
(1
.0
4–
3.
65
),
0.
03
8
30
9
1.
58
(1
.0
6–
2.
36
),
0.
02
6
30
7
1.
58
(1
.0
6–
2.
36
),
0.
02
6
44
5
1.
63
(1
.1
9–
2.
24
),
0.
00
24
48
3
D
at
a
ar
e
O
R
(9
5%
C
I),
P
va
lu
e
un
le
ss
ot
he
rw
is
e
in
d
ic
at
ed
.
B
ol
d
fa
ce
ty
p
e
in
d
ic
at
es
re
su
lts
th
at
ar
e
no
m
in
al
ly
si
gn
ifi
ca
nt
(P
,
0.
05
).
M
ac
ro
,
m
ac
ro
al
b
um
in
ur
ia
;
N
,
nu
m
b
er
of
p
ar
tic
ip
an
ts
.
4242 Genetic Evidence That Obesity Causes DKD Diabetes Volume 64, December 2015
independent cohorts lends strength to our findings. Fi-
nally, we note that our findings are limited to European
populations, as the variants used to construct our ge-
netic risk score were identified in European subjects
and the cohorts used in our study are all of European
descent.
Our findings support a causal role for obesity in de-
velopment of DKD but do not explain the underlying
mechanism. Obesity has well-known links to dyslipide-
mia, hypertension, and insulin resistance. Prior studies
in patients with type 1 diabetes suggest that some or
all of these risk factors are associated with increased
risk of complications. In the Diabetes Control and Com-
plications Trial (DCCT), investigators examined whether
the presence of metabolic syndrome (defined as central obe-
sity and presence of either raised triglycerides or hyper-
tension) or insulin sensitivity (represented by an estimated
glucose disposal rate [eGDR] calculated from the waist-to-
hip ratio, hypertension status, and HbA1c) at baseline was
associated with increased risk of complications. They found
that the most insulin-resistant patients (low eGDR) had
the highest risk of microvascular and macrovascular
complications; presence of the metabolic syndrome
had little predictive value (33). In the Pittsburgh Epi-
demiology of Diabetes Complications (EDC) Study, both
insulin resistance (measured by eGDR) and presence of
metabolic syndrome were associated with increased risk of
nephropathy, although the strength of the metabolic syn-
drome association depended on the criteria used (34). The
individual components of the metabolic syndrome (el-
evated triglycerides, hypertension, high waist-to-hip
ratio) were all predictive of major outcomes of diabetes
(coronary artery disease, renal failure, or death from
any diabetes-related cause). In an earlier study of the
FinnDiane cohort, the presence of metabolic syndrome
or any one of its components (increased waist circum-
ference, hypertension, elevated triglycerides, or low
HDL) was associated with increased risk of diabetic
nephropathy (20). Future well-powered Mendelian ran-
domization studies estimating the causal effects of tri-
glycerides or hypertension on DKD could help untangle
some of these questions.
Understanding the burden of obesity on patients with
type 1 diabetes has gained importance as rates of obesity
and overweight are on the rise both in the general pop-
ulation (35) and in those with type 1 diabetes (36–39).
Weight gain is a known adverse effect of intense glycemic
control (2); whether this type of insulin-induced weight
gain is influenced by genetic variants commonly associated
with BMI remains to be tested. Recent work from the
follow-up study of DCCT participants (the Epidemiology
of Diabetes Interventions and Complications [EDIC]) has
shown an association of excess weight gain with central
obesity, dyslipidemia, hypertension, and insulin resistance,
as well as more extensive atherosclerosis (40). Given recent
trends in obesity rates, our finding predicts a rise in rates
of kidney disease in the population with type 1 diabetes. If
further research validates our findings, weight management
Figure 2—Longitudinal associations between BMI and DKD outcomes, allowing for nonlinear effects, with 95% CI. Results obtained by
multivariable Cox regression (left y-axis) with restricted cubic splines with three knots for BMI, adjusted for age, sex, and duration of
diabetes at baseline, overlaying a histogram displaying the distribution of BMI (right y-axis, number of subjects).
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may become an important adjunct to glycemic control for
reducing complication risk.
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